143 related articles for article (PubMed ID: 9255370)
21. [Scleroderma--systemic sclerosis. Serology, lung function and survival].
Ullman S; Halberg P; Wiik A; Jacobsen S
Ugeskr Laeger; 1999 May; 161(21):3084-90. PubMed ID: 10377851
[TBL] [Abstract][Full Text] [Related]
22. Relationship between occupational risk factors and severity markers of systemic sclerosis.
Magnant J; de Monte M; Guilmot JL; Lasfargues G; Diot P; Asquier E; Degenne D; Boissinot E; Diot E
J Rheumatol; 2005 Sep; 32(9):1713-8. PubMed ID: 16142866
[TBL] [Abstract][Full Text] [Related]
23. Anticentromere antibodies in rheumatologic practice are not consistently associated with scleroderma.
Tubach F; Hayem G; Elias A; Nicaise P; Haim T; Kahn MF; Meyer O
Rev Rhum Engl Ed; 1997 Jun; 64(6):362-7. PubMed ID: 9513607
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics of scleroderma overlap syndromes: comparisons with pure scleroderma.
Foocharoen C; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R
Int J Rheum Dis; 2016 Sep; 19(9):913-23. PubMed ID: 27126733
[TBL] [Abstract][Full Text] [Related]
25. Scleroderma with type III glomerulonephritis and MPO-ANCA antibodies in the serum.
Herrera-Esparza R; Aguilar JL; Saucedo A; González I; López-Robles E; Avalos-Díaz E
J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):617-20. PubMed ID: 16164722
[TBL] [Abstract][Full Text] [Related]
26. [Anticentromere antibodies and other antinuclear antibodies in progressive systemic sclerosis].
Rojas C; Silva MC; Pérez L; Ruiz F
Rev Med Chil; 1985 May; 113(5):409-14. PubMed ID: 3912881
[No Abstract] [Full Text] [Related]
27. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis.
Giordano M; Valentini G; Migliaresi S; Picillo U; Vatti M
J Rheumatol; 1986 Oct; 13(5):911-6. PubMed ID: 3546686
[TBL] [Abstract][Full Text] [Related]
28. Anti-pm/scl antibodies in connective tissue disease: Clinical and biological assessment of 14 patients.
Vandergheynst F; Ocmant A; Sordet C; Humbel RL; Goetz J; Roufosse F; Cogan E; Sibilia J
Clin Exp Rheumatol; 2006; 24(2):129-33. PubMed ID: 16762146
[TBL] [Abstract][Full Text] [Related]
29. Anticardiolipin, anticentromere and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia.
Herrick AL; Heaney M; Hollis S; Jayson MI
Ann Rheum Dis; 1994 Aug; 53(8):540-2. PubMed ID: 7944641
[TBL] [Abstract][Full Text] [Related]
30. [Antinuclear, anticentromere and anti-ScL-70 antibodies in rheumatic diseases].
Ivanova SM; Melkumova KL; Il'in KV; Riazantseva TA; Piven' VA; Speranskiĭ AI
Lab Delo; 1990; (6):50-3. PubMed ID: 1699041
[TBL] [Abstract][Full Text] [Related]
31. [Pulmonary hypertension in patients with systemic scleroderma with CREST-syndrome and without it].
Karoli NA; Rebrov AP; Orlova EE
Ter Arkh; 2004; 76(5):15-8. PubMed ID: 15230125
[TBL] [Abstract][Full Text] [Related]
32. Limited cutaneous systemic sclerosis associated with discoid lupus erythematosus in two Japanese patients with anticentromere antibodies.
Kawakami T; Kawasaki K; Soma Y
Br J Dermatol; 2007 Dec; 157(6):1289-91. PubMed ID: 17927793
[No Abstract] [Full Text] [Related]
33. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis.
Scorza R; Caronni M; Bazzi S; Nador F; Beretta L; Antonioli R; Origgi L; Ponti A; Marchini M; Vanoli M
Ann N Y Acad Sci; 2002 Jun; 966():238-46. PubMed ID: 12114278
[TBL] [Abstract][Full Text] [Related]
34. Anticentromere antibody. Clinical Correlations and association with favorable prognosis in patients with scleroderma variants.
McCarty GA; Rice JR; Bembe ML; Barada FA
Arthritis Rheum; 1983 Jan; 26(1):1-7. PubMed ID: 6337593
[TBL] [Abstract][Full Text] [Related]
35. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis.
Jacobsen S; Ullman S; Shen GQ; Wiik A; Halberg P
J Rheumatol; 2001 Nov; 28(11):2454-9. PubMed ID: 11708418
[TBL] [Abstract][Full Text] [Related]
36. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
37. [Primary biliary cirrhosis and systemic scleroderma (Reynolds syndrome): apropos of 8 new cases. The contribution of accessory salivary gland biopsy].
Launay D; Hebbar M; Janin A; Hachulla E; Hatron PY; Devulder B
Rev Med Interne; 1998 Jun; 19(6):393-8. PubMed ID: 9775180
[TBL] [Abstract][Full Text] [Related]
38. The CREST syndrome: a distinct serologic entity with anticentromere antibodies.
Fritzler MJ; Kinsella TD
Am J Med; 1980 Oct; 69(4):520-6. PubMed ID: 6968511
[TBL] [Abstract][Full Text] [Related]
39. Serological markers in progressive systemic sclerosis: clinical correlations.
Catoggio LJ; Bernstein RM; Black CM; Hughes GR; Maddison PJ
Ann Rheum Dis; 1983 Feb; 42(1):23-7. PubMed ID: 6402991
[TBL] [Abstract][Full Text] [Related]
40. Anticentromere antibody: an immunological marker of a subset of systemic sclerosis.
Chorzelski TP; Jablonska S; Beutner EH; Blaszczyk M; Jarzabek-Chorzelska M; Kencka D; Krasny S; Kumar V; Tchórzewska A
Br J Dermatol; 1985 Oct; 113(4):381-9. PubMed ID: 3877519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
